Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing selective oral therapies for immune-mediated and neurologic diseases. Headquartered in New York, United States, the company concentrates on small-molecule drugs designed to modulate specific immune and inflammatory pathways while aiming to maintain convenient oral administration for patients. Its pipeline targets chronic inflammatory conditions and neuroinflammatory disorders where dysregulated immune responses play a central role. Immunic, Inc. works across key therapeutic areas such as multiple sclerosis and other autoimmune-related indications, positioning its candidates as potential alternatives or complements to injectable or infused treatments. In the broader healthcare and biotechnology market, the company contributes to innovation in immunology by advancing differentiated compounds through clinical development, collaborating with investigators, and engaging with regulatory bodies. Through this focus, Immunic, Inc. plays a role in the ongoing shift toward more targeted and patient-friendly approaches to managing complex immune-driven diseases.